Trial Profile
Definitive Chemoradiotherapy with the Addition of Lapatinib in Inoperable, Locally Advanced Oesophageal and OGJ Adenocarcinoma A Phase I study
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 17 Oct 2013 New trial record